Daiichinkyo Co (STU:D4S) FCF Margin % : -6.87% (As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Daiichinkyo Co's Free Cash Flow for the three months ended in Sep. 2024 was €-193 Mil. Daiichinkyo Co's Revenue for the three months ended in Sep. 2024 was €2,814 Mil. Therefore, Daiichinkyo Co's FCF Margin % for the quarter that ended in Sep. 2024 was -6.87%.

As of today, Daiichinkyo Co's current FCF Yield % is 5.01%.

The historical rank and industry rank for Daiichinkyo Co's FCF Margin % or its related term are showing as below:

STU:D4S' s FCF Margin % Range Over the Past 10 Years
Min: 2.73 Med: 8.03 Max: 29.75
Current: 25.17

During the past 13 years, the highest FCF Margin % of Daiichinkyo Co was 29.75%. The lowest was 2.73%. And the median was 8.03%.

STU:D4S's FCF Margin % is ranked better than
93.45% of 993 companies
in the Drug Manufacturers industry
Industry Median: 0.89 vs STU:D4S: 25.17

Daiichinkyo Co FCF Margin % Historical Data

The historical data trend for Daiichinkyo Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co FCF Margin % Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

Get a 7-Day Free Trial

14.67

13.31

5.99

3.69

29.75

Daiichinkyo Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-10.89	135.93	-4.06	-32.57	-6.87

Competitive Comparison of Daiichinkyo Co's FCF Margin %

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's FCF Margin % falls into.

Daiichinkyo Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Daiichinkyo Co's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	2925.869	/	9835.581
	=	29.75 %

Daiichinkyo Co's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-193.241	/	2814.495
	=	-6.87 %

Daiichinkyo Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Mexico 4568:Japan

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

No Headlines